CB2 Insights   Report issue

For profit Phase 2
Founded: Mississauga Canada (2014)

Organization Overview

First Clinical Trial
2020
NCT04267679
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

CB2 Insights

Active Ingredients

Drugs in Phase 2 Trials (1)

cannabidiol (Epidiolex) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anxiety Disorders (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1